Method for radiolabeling antibodies with yttrium-90
AssigneeBiogen Idec Inc.
InventorPaul Chinn
Life of this patent
Estimating the term…
Abstract
Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.
Claims21
1-48. (canceled)
A method for radiolabeling a chelator-conjugated antibody or antibody fragment with 90Y for administration to a patient comprising:
- (i) mixing the chelator-conjugated antibody or antibody fragment with a solution comprising 90Y or a salt thereof, and
- (ii) incubating the mixture for a sufficient amount of time under amiable conditions such that a 90Y-labeled antibody or antibody fragment is produced having sufficient radioincorporation, sufficient immunoreactivity, and a specific activity of at least about 5 mCi/mg, such that the 90Y-labeled antibody or antibody fragment may be administered directly to the patient without further purification of the 90Y-labeled radiolabeled antibody or antibody fragment from unincorporated 90Y;
- wherein said chelator is a bifunctional chelator selected from the group consisting of MX-DTPA, phenyl-DTPA, benzyl-DTPA, CHX-DTPA, DOTA and derivatives thereof.
A method for radiolabeling a MX-DTPA-conjugated 2B8 antibody or antibody fragment with 90Y for administration to a patient comprising:
- (i) mixing the MX-DTPA-conjugated antibody or antibody fragment with a solution comprising 90Y or a salt thereof, and
- (ii) incubating the mixture for a sufficient amount of time under acceptable temperature, pH and buffer conditions such that a 90Y-labeled antibody or antibody fragment is produced having sufficient radioincorporation sufficient immunoreactivity, and a specific activity of at least about 5 mCi/mg, such that the 90Y-labeled antibody or antibody fragment may be administered directly to the patient without further purification of the 90Y-labeled 2B8 antibody or antibody fragment from unincorporated 90Y.
Dependencies are inferred from the claim text.